Tags

Type your tag names separated by a space and hit enter

Donepezil in severe Alzheimer's disease.
Am J Alzheimers Dis Other Demen 2009 Jun-Jul; 24(3):185-92AJ

Abstract

In the severe stages of Alzheimer's disease, functional autonomy is lost, psychiatric and behavioral symptoms become increasingly troublesome, and cognitive deficits increase until most patients require complete care, usually in specialized nursing homes. Consequently,some health care professionals question the benefits of pharmacologic intervention during these later stages. Since primary care physicians are often first to see these patients, they have key roles in recognizing the benefits of treatment and initiating appropriate management and referral. Three prospective randomized clinical trials of donepezil in severe Alzheimer's disease have been conducted; these show donepezil treatment is associated with functional and cognitive benefits, although behavioral benefits were not consistently observed. Donepezil was well tolerated; side effects were transient, mild to moderately severe, and cholinergic in nature. Donepezil has strong data throughout the Alzheimer's disease spectrum and, therefore, represents a first-line monotherapy that can provide benefits to patients in all stages of Alzheimer's disease.

Authors+Show Affiliations

Karolinska Institutet, Stockholm, Sweden. bengt.winblad@ki.se

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19246572

Citation

Winblad, Bengt. "Donepezil in Severe Alzheimer's Disease." American Journal of Alzheimer's Disease and Other Dementias, vol. 24, no. 3, 2009, pp. 185-92.
Winblad B. Donepezil in severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2009;24(3):185-92.
Winblad, B. (2009). Donepezil in severe Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 24(3), pp. 185-92. doi:10.1177/1533317509332094.
Winblad B. Donepezil in Severe Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2009;24(3):185-92. PubMed PMID: 19246572.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donepezil in severe Alzheimer's disease. A1 - Winblad,Bengt, PY - 2009/2/28/entrez PY - 2009/2/28/pubmed PY - 2009/10/9/medline SP - 185 EP - 92 JF - American journal of Alzheimer's disease and other dementias JO - Am J Alzheimers Dis Other Demen VL - 24 IS - 3 N2 - In the severe stages of Alzheimer's disease, functional autonomy is lost, psychiatric and behavioral symptoms become increasingly troublesome, and cognitive deficits increase until most patients require complete care, usually in specialized nursing homes. Consequently,some health care professionals question the benefits of pharmacologic intervention during these later stages. Since primary care physicians are often first to see these patients, they have key roles in recognizing the benefits of treatment and initiating appropriate management and referral. Three prospective randomized clinical trials of donepezil in severe Alzheimer's disease have been conducted; these show donepezil treatment is associated with functional and cognitive benefits, although behavioral benefits were not consistently observed. Donepezil was well tolerated; side effects were transient, mild to moderately severe, and cholinergic in nature. Donepezil has strong data throughout the Alzheimer's disease spectrum and, therefore, represents a first-line monotherapy that can provide benefits to patients in all stages of Alzheimer's disease. SN - 1938-2731 UR - https://www.unboundmedicine.com/medline/citation/19246572/Donepezil_in_severe_Alzheimer's_disease_ L2 - http://journals.sagepub.com/doi/full/10.1177/1533317509332094?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -